Clinical Trial

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Protocol Amendment History 1 change
notable Trial sites expanded: 23 -> 26 locations 2026-06-12
Trial Details
NCT Number NCT05433142
Lead Sponsor Xencor, Inc.
Conditions Clear Cell Renal Cell Carcinoma
Enrollment 307 participants
Start Date 2022-06-13
Primary Completion 2027-02 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-03